Table 3.
Unadjusted and adjusted analyses of treatment benefit by HOXB13/IL17BR (H/I) groups
| Variable | Unadjusted OR (95% CI) | P | Adjusted OR (95% CI) | P |
|---|---|---|---|---|
| Age, post- vs premenopausal | 0.25 (0.02 to 2.76) | .26 | 0.13 (0.01 to 1.60) | .11 |
| Tumor size, T2 + T3 vs T1 | 1.00 (0.23 to 4.35) | 1.00 | 1.13 (0.21 to 6.00) | .88 |
| Grade, 3 vs 1–2 | 1.56 (0.82 to 2.98) | .18 | 1.23 (0.58 to 2.60) | .59 |
| ER status, positive vs negative | 0.67 (0.15 to 2.98) | .60 | 0.83 (0.15 to 4.72) | .83 |
| PR status, positive vs negative | 1.05 (0.53 to 2.09) | .88 | 1.33 (0.62 to 2.86) | .46 |
| HER2 status, positive vs negative | 1.32 (0.55 to 3.18) | .54 | 0.99 (0.35 to 2.78) | .98 |
| Node status, positive vs negative | 1.00 (0.06 to 15.99) | 1.00 | 1.93 (0.11 to 33.77) | .65 |
| Treatment effect, letrozole vs placebo | ||||
| H/I-low | 0.68 (0.31 to 1.52) | .35 | 0.58 (0.25 to 1.36) | .21 |
| H/I-high | 0.35 (0.16 to 0.75) | .007 | 0.33 (0.15 to 0.73) | .006 |
* Odds ratio (OR), 95% confidence interval (CI), and P values were calculated from conditional logistic regression. All statistical tests were two-sided. ER = estrogen receptor; PR = progesterone receptor.